Non-Proliferative Diabetic Retinopathy Market Size Share and Industry Outlook to 2028
Added: (Thu Feb 24 2022)
Pressbox (Press Release) -
Global Non-Proliferative Diabetic Retinopathy Market is segmented By Type (Mild, Moderate, Severe), By Treatment Type (Anti-Vascular Endothelial Growth Factor drug, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centres), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028
Market Overview
The Global Non-Proliferative Diabetic Retinopathy Market is expected to grow at a CAGR of 7.30% during the forecasting period (2021-2028).
Non-Proliferative Diabetic Retinopathy (NPDR), also known as background retinopathy, is an early stage of diabetic retinopathy.
In NPDR, tiny blood vessels within the retina leak blood or fluid, which causes the retina to swell or form deposits.
The global Non-Proliferative Diabetic Retinopathy market is estimated to reach USD 2.5 billion by 2022.
Download Free Sample: https://www.datamintelligence.com/download-sample/non-proliferative-diabetic-retinopathy-market
Market Growth
The increasing prevalence of diabetes is the prime factor driving the growth of the Non-Proliferative Diabetic Retinopathy market.
Globally, an estimated 422 million adults are living with diabetes. Also, lack of diagnosis at the right time and non-compliant retinal screening of diabetic patients are predicted to drive the growth of the NPDR market.
However, the lack of skilled professionals, the extended approval time for drugs in conjunction with the strict regulatory requirements will restrict the market growth.
Market Segmentation Analysis
Global Non-Proliferative Diabetic Retinopathy market report segments the market by type, treatment type, end-user, and by region.
Based on disease severity level, the market is segmented into mild, moderate, and severe.
Based on treatment type, the market is segmented into Anti-VEGF therapy, intraocular steroid injection, laser surgery, and vitrectomy.
The anti-VEGF segment dominated the market in 2017 owing to high applicability in the treatment of early diagnosis and mild to moderate cases of NPDR.
Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
North America will dominate the market due to the high prevalence of diabetes, high awareness among people about Non-Proliferative Diabetic Retinopathy, availability of treatment options, and better reimbursement policies in the region.
Market Scope of the report
The report also profiles companies in the Non-Proliferative Diabetic Retinopathy market – Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche, Novartis International AG, Pfizer, Regeneron Pharmaceuticals Inc., and Valeant Pharmaceutical.
By Type
• Mild
• Moderate
• Severe
By Treatment Type
• Anti-Vascular Endothelial Growth Factor (VEGF) drug
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy
By End-User
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
By Region
• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
• North America (The USA, Canada, Mexico)
• South America (Brazil, Argentina, Rest of South America)
• Rest of the World
Why purchase the report?
Visualize the composition of the Non-Proliferative Diabetic Retinopathy market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the market – level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for critical Non-Proliferative Diabetic Retinopathy products of all major market players.
Target Audience
• Equipment Suppliers/ Buyers
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers
Trending Topics
• Diabetic Retinopathy Market
• Diabetic Macular Edema Market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com